The clinical efficacy of artificial pleural effusion combined with radiofrequency ablation in patients with phrenic top liver cancer

doi:10.11958/20250709

Abstract

Abstract:

Objective To explore the effect of artificial pleural effusion combined with radiofrequency ablation in patients with phrenic top liver cancer. Methods A total of 92 patients with liver tumors at top of the diaphragm were prospectively selected and divided into the control group (46 cases, radiofrequency ablation) and the observation group (46 cases, radiofrequency ablation + artificial pleural effusion) by the random number table method. Clinical outcomes one month after treatment, time to first surgical ablation, serum alpha-fetoprotein (AFP) levels and complications before treatment and one month after treatment were compared. Both groups were followed up for 2 years after the operation, and survival conditions of patients were compared. Results Enhanced MRI or enhanced CT at 1 month after surgery in the 2 groups showed that the complete tumor ablation rate was lower in the control group than that in the observation group (76.09% vs. 93.48%, P<0.05). The surgical ablation time of the observation group was shorter than that of the control group [(9.64±1.22) min vs. (11.15±1.47) min, P<0.05]. The survival rates were higher in the observation group than those in the control group at 1 year (82.61% vs. 58.70%) and 2 years (71.74% vs. 47.83%) after treatment (P<0.05). Serum AFP levels decreased in both groups after treatment, and those were lower in the observation group than those in the control group (P<0.05). The total complication rate of the observation group was lower than that of the control group (8.70% vs. 23.91%, P<0.05). The follow-up period of 92 patients ranged from 7 to 29 months, with a mean of (20.17±4.61) months. The local tumor progression rate was higher in the control group than that in the observation group during the follow-up period (36.96% vs. 10.87%, P<0.05). Conclusion Artificial pleural effusion combined with radiofrequency ablation can effectively improve the clinical efficacy and survival rate of patients with liver cancer, reduce the level of serum AFP and decrease the occurrence of complications.

Key words: liver neoplasms, hydrothorax, radiofrequency ablation, alpha-fetoproteins, clinical effect

CLC Number:

R735.7，R454.1，R561.3

Figures/Tables 3

References 19

[1]	XUE Y, RUAN Y, WANG Y, et al. Signaling pathways in liver cancer:pathogenesis and targeted therapy[J]. Mol Biomed, 2024, 5(1):20. doi:10.1186/s43556-024-00184-0.
[2]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi:10.3322/caac.21834.
[3]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231.
	ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China,2022[J]. Chin J Oncol, 2024, 46(3):221-231. doi:10.3760/cma.j.cn112152-20240119-00035.
[4]	HAMAYA S, OURA K, MORISHITA A, et al. Cisplatin in liver cancer therapy[J]. Int J Mol Sci, 2023, 24(13):10858. doi:10.3390/ijms241310858.
[5]	CAI Y, WANG W, JIAO Q, et al. Nanotechnology for the diagnosis and treatment of liver cancer[J]. Int J Nanomedicine, 2024, 19:13805-13821. doi:10.2147/IJN.S490661.
[6]	CHEN Z, WANG J, LIN Y. Comparison of the efficacy and safety of repeated hepatectomy and radiofrequency ablation in the treatment of primary recurrent liver cancer:a meta-analysis[J]. World J Surg Oncol, 2022, 20(1):182. doi:10.1186/s12957-022-02649-4.
[7]	SPILIOTIS A E, GÄBELEIN G, HOLLÄNDER S, et al. Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer:a systematic review and meta-analysis[J]. Radiol Oncol, 2021, 55(3):247-258. doi:10.2478/raon-2021-0030.
[8]	蓝思荣, 张耀明, 温苑章, 等. 人工胸腹水在微波消融治疗肝癌中的应用价值[J]. 广州医科大学学报, 2021, 49(1):51-53.
	LAN S R, ZHANG Y M, WEN Y Z, et al. Usefulness of artificial ascites in microwave ablation of liver cance[J]. Academic Journal of Guangzhou Medical College, 2021, 49(1):51-53. doi:10.3969/j.issn.2095-9664.2021.01.14.
[9]	中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华肝脏病杂志, 2017, 25(12):886-895.
	Bureau of Medical Administration, National Health and Family Planning Comission of the PRC. Standardization of diagnosis and treatment for hepatocellular carcinoma(2017 edition)[J]. Chin J Hepatol, 2017, 25(12):886-895. doi:10.3969/j.issn.1001-5256.2017.08.003
[10]	中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作委员会, 中华医学会分会肝癌学组. 肝癌射频消融治疗规范的专家共识[J]. 临床肝胆病杂志, 2011, 27(3):236-238,244.
	Chinese Expert Consensus Statement Chinese Society of Live Cancer(CSLC), Chinese Society of Clinical Oncology(CSCO), Liver Cancer Group,Chinese Society of Hepatology. Guidelines for radiofrequency ablation therapy of liver cancer[J]. J Clin Hepatol, 2011, 27(3):236-238,244. doi:10.3969/j.issn.1001-5256.2011.03.003.
[11]	WANG Y, DENG B. Hepatocellular carcinoma:molecular mechanism,targeted therapy,and biomarkers[J]. Cancer Metastasis Rev, 2023, 42(3):629-652. doi:10.1007/s10555-023-10084-4.
[12]	GILLES H, GARBUTT T, LANDRUM J. Hepatocellular carcinoma[J]. Crit Care Nurs Clin North Am, 2022, 34(3):289-301. doi:10.1016/j.cnc.2022.04.004.
[13]	黄国林, 蓝晓步, 秦艳娥, 等. 环状RNA在肝癌耐药中的作用及机制研究进展[J]. 中国药理学通报, 2023, 39(1):13-17.
	HUANG G L, LAN X B, QIN Y E, et al. Research progress of circular RNA in drug resistance of liver cancer[J]. Chinese Pharmacology Bulletin, 2023, 39(1):13-17. doi:10.12360/CPB202101059.
[14]	DENG Q, HE M, FU C, et al. Radiofrequency ablation in the treatment of hepatocellular carcinoma[J]. Int J Hyperthermia, 2022, 39(1):1052-1063. doi:10.1080/02656736.2022.2059581.
[15]	赵孟杰, 邢恩涛, 董源, 等. 不可逆电穿孔和射频消融治疗原发性肝癌效果比较[J]. 青岛大学学报(医学版), 2024, 60(1):110-114.
	ZHAO M J, XING E T, DONG Y, et al. Efficacy of irreversible electroporation versus radiofrequency ablation for primary liver cancer[J]. Journal of Qingdao University(Medical Sciences), 2024, 60(1):110-114. doi:10.11712/jms.2096-5532.2024.60.006.
[16]	蒋彪, 付彤, 吴旭栋. 高强度聚焦超声联合人工液胸治疗不可切除小儿肝母细胞瘤短期疗效研究[J]. 实用肝脏病杂志, 2022, 25(6):893-896.
	JIANG B, FU T, WU X D. Short-term efficacy of high intensity focused ultrasound with auxiliary artificial plethorax in the treatment of children with unresectable hepatoblastoma[J]. J Prac Hepatol, 2022, 25(6):893-896. doi:10.3969/j.issn.1672-5069.2022.06.034.
[17]	陈建, 金霞, 陈晓, 等. 人工腹水对膈面、脏面原发性肝癌微波消融治疗中的应用价值[J]. 实用临床医药杂志, 2019, 23(6):7-12.
	CHEN J, JIN X, CHEN X, et al. Value of artificial ascites in the treatment of primary hepatocelluar carcinoma under diaphragmatic and the visceral surface by percutaneous microwave ablation[J]. Journal of Clinical Medicine Practice, 2019, 23(6):7-12. doi:10.7619/jcmp.201906002.
[18]	卢晶, 张雅敏, 李华, 等. 血清甲胎蛋白联合碱性磷酸酶评分对可切除肝细胞癌患者预后的预测价值[J]. 临床肝胆病杂志, 2023, 39(3):599-605.
	LU J, ZHANG Y M, LI H, et al. Value of a scoring system based on the serum levels of alpha-fetoprotein and alkaline phosphatase in predic-ting the prognosis of patients with resectable hepatocellular carcinoma[J]. J Clin Hepatol, 2023, 39(3):599-605. doi:10.3969/j.issn.1001-5256.2023.03.017.
[19]	谭玉莹, 张炜琪, 谢炎, 等. 肝细胞癌微血管侵犯相关危险因素分析及预测模型的构建[J]. 天津医药, 2022, 50(5):523-527.
	TAN Y Y, ZHANG W Q, XIE Y, et al. The risk factor analysis and predictive model construction of microvascular invasion in hepatocellular carcinoma[J]. Tianjin Med J, 2022, 50(5):523-527. doi:10.11958/20212723.

组别	治疗前	治疗后	t
对照组	359.77±46.28	97.84±22.16	32.421^＊＊
观察组	368.54±41.22	79.85±14.63	43.884^＊＊
t	0.960	4.591^＊

组别	治疗前	治疗后	t
对照组	359.77±46.28	97.84±22.16	32.421^＊＊
观察组	368.54±41.22	79.85±14.63	43.884^＊＊
t	0.960	4.591^＊

组别	n	肺损伤	皮下水肿	肝区疼痛	发热	总发生
对照组	46	2（4.35）	3（6.52）	3（6.52）	3（6.52）	11（23.91）
观察组	46	1（2.17）	1（2.17）	1（2.17）	1（2.17）	4（8.70）
χ²						3.903^＊

组别	n	肺损伤	皮下水肿	肝区疼痛	发热	总发生
对照组	46	2（4.35）	3（6.52）	3（6.52）	3（6.52）	11（23.91）
观察组	46	1（2.17）	1（2.17）	1（2.17）	1（2.17）	4（8.70）
χ²						3.903^＊